Sangamo Therapeutics (NASDAQ:SGMO) Rating Lowered to “Hold” at StockNews.com

Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a report released on Tuesday.

A number of other research firms have also commented on SGMO. Barclays raised their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, December 19th. Finally, Truist Financial upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.00.

Sangamo Therapeutics Stock Up 4.6 %

NASDAQ SGMO opened at $2.50 on Tuesday. The company has a market cap of $521.62 million, a PE ratio of -3.33 and a beta of 1.15. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18. The firm’s 50-day simple moving average is $2.06 and its two-hundred day simple moving average is $1.18.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The company had revenue of $49.41 million for the quarter, compared to analysts’ expectations of $26.55 million. During the same period in the prior year, the company posted ($0.34) EPS. As a group, equities research analysts anticipate that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Meritage Portfolio Management raised its holdings in shares of Sangamo Therapeutics by 8.6% in the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 6,740 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in Sangamo Therapeutics by 55.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Sangamo Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after purchasing an additional 57,125 shares during the last quarter. XTX Topco Ltd grew its stake in Sangamo Therapeutics by 167.8% in the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 64,981 shares in the last quarter. Finally, Golden State Equity Partners increased its holdings in shares of Sangamo Therapeutics by 35.2% in the 3rd quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 69,368 shares during the last quarter. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.